ESSA Pharma Announced Data Combination Of Masofaniten Plus Enzalutamide Continues To Be Well Tolerated With Deep And Durable Reductions In PSA In Patients With Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the
